A 65-year-old Caucasian male previously followed in our institution for a Binet A-stage chronic lymphocytic leukemia (CLL) presented for checkup. The patient had no particular complaint except being a little more tired than usual. Clinical examination revealed a splenomegaly but no other adenopathies, no fever, or weight loss.
Tests run on the plasma showed no particularity except elevated LDH (1198 UI/L, usual range 0-470), complete blood count showed a mild anemia (Hemoglobin = 120 g/L), thrombocytosis (platelets = 627 G/L), elevated leucocytes (120 G/L), and the automated analyzer notified numerous errors leading to a blood film examination (Figure 1 ). Beside 19% of the habitual CLL mature lymphocytes (19.39 × 10 9 /L), we observed a very important increase in neutrophils and a myelemia accounting all together for 67% (80.4 × 10 9 /L) of the nucleated cells. Eosinophils and basophils accounted, respectively, for 8% (9.7 × 10 9 /L) and 5% (6.06 × 10 9 /L) of the nucleated cells. This combination of findings suggested the diagnosis of a de novo chronic myeloid leukemia (CML). This hypothesis was later confirmed by cytogenetic analysis, with a Philadelphia chromosome in all the 29 mitosis analyzed, and by the molecular analysis with a positive M-BCR/ABL transcript. CLL features had remained unchanged since his last checkup (ie, a 5 Matutes score and a karyotype showing a del13q).
As the patient's CLL had remained stable and the CML was at its chronic phase, it was decided to treat primarily the CML with 400 mg daily of imatinib.
CLL and CML are two of the most common leukemias among adults in western countries, but the occurrence of both of the diseases in the same patient is a very unusual situation and literature reporting those associations remains scarce. In most reports, CML diagnosis follows CLL diagnosis, and molecular and cytogenetic studies suggest malignancies emerged from distinct clones.
